Company: DARE
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001401914-25-000012
Chunk: 22

Company: Dare Bioscience, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 22
---
755,884 126 %Sildenafil Cream, 3.6%2,361,052 7,746,264 (5,385,212)(70)%Other advanced clinical stage programs1,321,888 3,498,955 (2,177,067)(62)%Phase 1 and Phase 1-ready clinical stage programs (1)761,721 2,912,857 (2,151,136)(74)%Preclinical stage programs (1)4,233,762 7,432,439 (3,198,677)(43)%Other development programs27,542 189,706 (162,164)(85)%Contra R&D expenses (2)(7,685,533)(8,965,347)1,279,814 (14)%Total direct program costs9,538,927 16,577,485 (7,038,558)(42)%Indirect costs:Personnel-related (including stock compensation)5,611,057 5,566,016 45,041 1 %Outside services (including consulting)543 38,114 (37,571)(99)%Facilities-related (including depreciation)78,168 86,239 (8,071)(9)%Other indirect R&D costs176,061 259,936 (83,875)(32)%Contra R&D expenses(1,199,548)(989,716)(209,832)21 %Total indirect R&D costs4,666,281 4,960,589 (294,308)(6)%Total R&D expenses$14,205,208 $21,538,074 $(7,332,866)(34)%(1)The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (2) below. (2)These contra R&D expenses were recognized as follows for the years ended December 31, 2024 and 2023: (a) Ovaprene, $0.2 million, and $0, respectively; (b) Other advanced clinical stage programs, $0 and $0.1 million, respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $1.3 million and